Internet Archive Scholar

Zoledronic acid versus placebo in pediatric glucocorticoid-induced osteoporosis: A randomized double-blind phase 3 trial

Leanne M Ward, Anup Choudhury, Nathalie Alos, David A Cabral, Celia Rodd, Anne Marie Sbrocchi, Shayne Taback, Raja Padidela, Nick J Shaw, Eva Hosszu, Mikhail Kostik, Ekaterina Alexeeva (+7 others)
2021 Journal of Clinical Endocrinology and Metabolism  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (459.1 kB)
https://web.archive.org/web/20211128123917/https://watermark.silverchair.com/dgab458.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAsswggLHBgkqhkiG9w0BBwagggK4MIICtAIBADCCAq0GCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMQZgOYk5sXMTOulsgAgEQgIICftrtZXI0asuZNcFen3FIVaTKZstjNkFjx8a5Z1T6Uhf6gKu239cUHsimQ8LncX3zHx7dY45XkRUARzwE8in6NsSPaEps7VAMQpI8Iu9_XY8Yzv9hUf3po_cPC0zs7H23I_EfdEDCVXeoOoN7hVNjCpZ76RAEmUZ3BDPvUGLVRUKBByqheYwXN3fgHgJuhapJCGl8uk6P6PdtOyNzZZLeL-yqLAODI8fr1Al1MMnGaRJDVvI2E0-onUsM40YA8Z0BpMC6dQid-egyZQr-rvEabQzffF4zzt_DkzMIquGVyT3Cs3now5em7EuFRCuHed_lhYSek8_OrmCJkctQjtT2lNtqJVwmXmAY7aDjcsdmWT733JDfpcoUsl9U9NkQ7KzPyXWSH6hQBrTAqdchJF3Ohai57TCOzUyJhviN60BDQwSkTYh5tDHhicpBQJM7176xybZd1Wt9IKixbCTSRSS6BiOPQC7BKCJ-RlDwy_bkqJMoQvf6boUcSkGeMjfv5FwJwAoOfNa8IX9-YKwN22Qs3Ks0GA7XeSKFR78xhvLB2vieuqALArppVn_IX3Nfi2lTsId9EtAr5-XLH_0HWUOIEkjkfgUkASy7PPLH34AsMOr9wNeFFYKIO3-jL9qm2bU5NJzCBFxJL4aC0X2LsQ0VYOlgk9zBqYSY_dGQswZYfSeZqC_DN2B4SCqq4MTCThY7KYNOrlu2ryEaUyNZ2U9lN3ygebg6xtC4GGeefPHrEFqWnbn2Nd2UNYw0a4sEfSU06U0RUoZmL8r3ThiOoI01AD01HEfUS2YhH2uS6TLJElqRYx52klxF8YrrCTEASe6Q-qZFYZMLyVYaCARi1uy4

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL. The file type is application/pdf.

Context Glucocorticoids (GC) prescribed for chronic pediatric illnesses are associated with osteoporotic fractures. Objective To determine the efficacy and safety of intravenous (IV) zoledronic acid (ZA) compared with placebo to treat pediatric GC-induced osteoporosis (GIO). Patients, Design and Setting Children 5-17 years of age with GIO were enrolled in this multi-national randomized, double-blind, placebo-controlled phase 3 trial (ClinicaTrials.gov NCT 00799266). Interventions and Main
more » ... e Measures Eligible children were randomized 1:1 to six monthly IV ZA 0.05 mg/kg or IV placebo. The primary endpoint was the change in lumbar spine bone mineral density Z-score (LSBMDZ) from baseline to month 12. Incident fractures and safety were assessed. Results Thirty-four children were enrolled (mean age 12.6 ± 3.4 years [18 on ZA, 16 on placebo]), all with low-trauma vertebral fractures. LSBMDZ increased from −2.13 ± 0.79 to −1.49 ± 1.05 on ZA, compared with −2.38 ± 0.90 to −2.27 ± 1.03 on placebo (least squares means difference 0.41 [95% confidence interval 0.02, 0.81; p=0.04]); when corrected for height Z-score, the least squares means difference in LBMDZ was 0.75 [0.27, 1.22; p=0.004]. Two children on placebo had new low-trauma VF versus none on ZA. Adverse events (AEs) were reported in 15/18 children (83%) on ZA, and in 12/16 (75%) on placebo, most frequently within 10 days after the first infusion. There were no deaths, nor treatment discontinuations due to treatment-emergent AEs. Conclusions LSBMDZ increased significantly on ZA compared with placebo over one year in children with GIO. Most AEs occurred after the first infusion.
doi:10.1210/clinem/dgab458 pmid:34228102 fatcat:yfzqgnp7jjgs7eqfdi43q2nj5m
Citation

Leanne M Ward, Anup Choudhury, Nathalie Alos, David A Cabral, Celia Rodd, Anne Marie Sbrocchi, Shayne Taback, Raja Padidela, Nick J Shaw, Eva Hosszu, Mikhail Kostik, Ekaterina Alexeeva, Kebashni Thandrayen, Nazih Shenouda, Jacob L Jaremko, Gangadhar Sunkara, Sarfaraz Sayyed, R Paul Aftring, Craig F Munns. "Zoledronic acid versus placebo in pediatric glucocorticoid-induced osteoporosis: A randomized double-blind phase 3 trial." Journal of Clinical Endocrinology and Metabolism (2021)